Alnylam Pharmaceuticals
ALNY
#638
Rank
C$45.07 B
Marketcap
$347.39
Share price
-0.59%
Change (1 day)
39.23%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.85. In 2022 the company made an earnings per share (EPS) of -$13.23 a decrease over its 2021 EPS that were of -$10.25.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-58.44%
2022-$13.2329.03%
2021-$10.25-3.36%
2020-$10.61-8.48%
2019-$11.597.67%
2018-$10.7639.74%
2017-$7.7012.94%
2016-$6.8238.84%
2015-$4.91-32.88%
2014-$7.32259.44%
2013-$2.04-31.25%
2012-$2.9652.94%
2011-$1.9430.77%
2010-$1.48-8.77%
2009-$1.6278.13%
2008-$0.91-70.78%
2007-$3.1299.09%
2006-$1.57-43.88%
2005-$2.79-82.33%
2004-$15.79-59.23%
2003-$38.74

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.42-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$53.19-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$11.15 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.38-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.41-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.33-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.53-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.85-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel